Alex Friedlaender
Geneve, GE 1206, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 111 publications
Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas.
Journal: International journal of molecular sciences
Published: December 29, 2025
Personalized cancer vaccines and their integration with standard of care modalities.
Journal: Cancer treatment reviews
Published: October 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Journal: Journal for immunotherapy of cancer
Published: July 31, 2025
Precision oncology in rare tumors: Have the orphans been adopted?
Journal: Med (New York, N.Y.)
Published: June 04, 2025
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications.
Journal: International journal of molecular sciences
Published: March 08, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2024
Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume II.
Journal: Frontiers in endocrinology
Published: July 05, 2024
First-line immunotherapy in non-small cell lung cancer: how to select and where to go.
Journal: Expert review of respiratory medicine
Published: January 31, 2024
Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice.
Journal: Journal of gastrointestinal oncology
Published: January 10, 2024
Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatment.
Journal: Immunotherapy
Published: December 19, 2023
Last Updated: 09/26/2026